title: [Clinical study of three-dose regimen of Zenapax in orthotopic liver transplantation].
abstract: OBJECTIVE
  To observe the clinical efficacy and safety of three-dose regimen of Zenapax combined with tacrolimus (FK506), mycophenolate mofetil (MMF), and steroid in the early-stage management of liver transplantation.
  
  
  METHODS
  Thirteen liver transplantation recipients received the same immunosuppression regimen with three-dose Zenapax combined with FK506, MMF, and steroid. The incidence of acute allograft rejection (AR), blood concentration and dosage of FK506, and the liver graft function were observed in the 30 days after liver transplantation and compared with the results documented in literatures.
  
  
  RESULTS
  One patient developed AR 17 days after transplantation and 3 patients died on the postoperative days 14, 19 and 23, respectively, due to pulmonary fungal infection, acute hepatic failure or multiple organ failure resulting from stenosis and thrombosis of hepatic artery respectively. Ten recipients had various infections. An average of 16.56+/-10.40 d was taken for functional recovery of the liver graft, and the blood concentration of FK506 was maintained at (10.25+/-1.99)x10(-3) mg/L. Anaphylaxis, post-transplant lymphoproliferative disorder (PTLD), or other adverse effects were not observed.
  
  
  CONCLUSIONS
  Three-dose regimen of Zenapax in combination with FK506, MMF and steroid is safe and effective in the postoperative management of orthotopic liver transplantation.
authors.affiliation: Department of Kidney Transplantation, Nanfang Hospital, First Military Medical University, Guangzhou 510515, China. hegang87@126.com
authors.forename: Gang
authors.initials: G
authors.lastname: He
authors.forename: Li-xing
authors.initials: LX
authors.lastname: Yu
authors.forename: Wen-feng
authors.initials: WF
authors.lastname: Deng
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000077561:Daclizumab; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage* / Q000009:adverse effects; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D016031:Liver Transplantation / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives*; D015996:Survival Rate; D016559:Tacrolimus / Q000008:administration & dosage / Q000097:blood
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000077561:Daclizumab; D009173:Mycophenolic Acid; D016559:Tacrolimus